)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories (DRREDDY) investor relations material
Dr. Reddy’s Laboratories Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary23 Oct, 2026
Executive summary
Q2FY27 revenue was INR 8,671 crore, down 1.5% YoY and up 7.4% QoQ; underlying base business grew at a double-digit rate excluding North American lenalidomide.
EBITDA was INR 1,783 crore at a 20.6% margin; attributable profit was INR 925 crore.
H1FY27 revenue declined 3.5% YoY to INR 167.4bn, EBITDA fell 40% to INR 27.9bn and attributable profit fell 52% to INR 13.7bn.
Financial highlights
Consolidated revenue was INR 8,671 crore ($905 million); new launches, favorable FX and base-business growth partly offset lower lenalidomide sales.
EBITDA was INR 1,783 crore; PBT was INR 1,228 crore and PAT attributable to equity holders was INR 925 crore.
SG&A rose 6% YoY to INR 2,808 crore; R&D declined 16% YoY to INR 524 crore.
Outlook and guidance
Gross margin is expected to remain within 50%-55%; management expects EBITDA margin above 20% and targets 25% over time.
Semaglutide relaunch is targeted for November 2026, subject to validation; FY device guidance is 6-7 million, with a tentative 12-15 million pen run rate discussed for the following 12 months from April.
R&D is expected at 7%-8% of revenue in coming quarters; FY CapEx guidance is INR 1,600-INR 1,700 crore.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dr. Reddy’s Laboratories
- Record FY21 revenue and EBITDA; Sputnik V launch broadened the Covid portfolio.DRREDDY
Q4 20/21 - Record sales, 20% adjusted growth, and lower gross margin shaped Q2 FY21.DRREDDYQ2 20/21
- Record FY23 sales and EBITDA, backed by launches, pipeline progress and strong cash generation.DRREDDYQ4 22/23
- Revenue rose 29% as launches and market gains fueled record Q1 FY24 profitability.DRREDDYQ1 23/24
- FY23 growth and cash generation support a 1.5bn-patient, innovation-led expansion.DRREDDYInvestor presentation
- Record Q2 sales and broad-based growth, backed by launches and robust profitability.DRREDDYQ2 23/24
- Record FY24 revenues and profits, with Q4 growth led by US volumes and launches.DRREDDYQ4 23/24
- Revenue rose 7% as launches and market-share gains supported Q3FY24 growth.DRREDDYQ3 23/24
- Record ₹7,673 Cr revenue, 28.2% EBITDA margin, and major strategic deals in Q1FY25.DRREDDYQ1 24/25
Next Dr. Reddy’s Laboratories earnings date
Q3 26/2720 Jan, 2027
Dr. Reddy’s Laboratories
Next Dr. Reddy’s Laboratories earnings date
Q3 26/2720 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Dr. Reddy’s Laboratories, an integrated pharmaceutical company worldwide, discovers, develops, manufactures and markets innovative branded generic pharmaceuticals and formulations in specialty areas primarily neurology and psychiatry. The company also markets and distributes products, including pharmaceutical intermediates and active pharmaceutical ingredients (APIs); animal health-related products; nutraceuticals/food supplements; and chemicals. The company offers a range of products comprising of tablets, capsules, fine granules, liquids and injectable pharmaceuticals, transdermal patches, ointments, creams, sprays and others. It markets its products through wholesalers and distributors to pharmacies, pharmacists and hospitals; chain drug stores; mass market retailers; e-commerce websites; government institutions; missionary organizations; etc.